Vurdering af reguleringsmæssige behov - liste
Vurdering af reguleringsmæssige behov - liste
The assessment of regulatory needs list includes substances for which an assessment either is under development or has been completed.
For each substance, the table shows the assessing authority (submitter), the concern, the status and the suggested follow-up action, and the date of the latest update to the list entry.
Other process details and relevant documents are also available and can be accessed through the ‘Details’ icon for the list entry.
Regulatory Management Option Analysis (RMOA) are assessments of regulatory needs. Publication of RMOA was initiated in February 2013 with the start of the implementation of the SVHC Roadmap. In 2019, authorities and in particular ECHA have moved to address more groups of substances.
The responsibility for the content of an assessment of regulatory needs rests with the authority that developed it. It is possible that other authorities do not have the same view and may develop a further assessment of regulatory needs for the same (group of) substances. Assessment of regulatory needs and their conclusions are compiled based on available information and may change in light of new information or further assessment.
Last updated 23 april 2024. Database contains 4860 unique substances/entries.
Filter the list
The List does not contain any Substances.
|
206-196-6
|
307-24-4
|
Germany
|
Other environmental toxicity |
Concluded
|
SVHC
|
07-dec.-2017
|
Details | |
|
203-293-5
|
105-38-4
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
None
|
11-dec.-2020
|
Details | |
|
203-545-4
|
108-05-4
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
None
|
11-dec.-2020
|
Details | |
|
231-639-5
|
7664-93-9
|
Belgium
|
Carcinogenic Exposure Mutagenic |
Under development
|
No suggestion yet
|
Details | ||
|
240-715-7
|
16669-59-3
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
Other legislation
|
25-aug.-2021
|
Details | |
|
222-871-8
|
3644-11-9
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
Other legislation
|
25-aug.-2021
|
Details | |
|
213-103-2
|
924-42-5
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
SVHC
|
25-aug.-2021
|
Details | |
|
217-442-7
|
1852-16-0
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
CLH
|
25-aug.-2021
|
Details | |
|
679-769-5
|
2675-94-7
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
None
|
25-aug.-2021
|
Details | |
|
203-750-9
|
110-26-9
|
Sweden
|
Carcinogenic Mutagenic |
Concluded
|
CLH
|
25-aug.-2021
|
Details | |
|
205-288-3
|
137-30-4
|
Denmark
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
202-924-1
|
101-20-2
|
France
|
Endocrine disruption |
Concluded
|
Other
|
09-aug.-2018
|
Details | |
|
201-067-0
|
77-90-7
|
France
|
Endocrine disruption |
Concluded
|
None
|
07-nov.-2016
|
Details | |
|
201-071-2
|
77-94-1
|
France
|
Endocrine disruption |
Concluded
|
Other legislation
|
30-sep.-2016
|
Details | |
|
260-830-6
|
57583-54-7
|
France
|
Endocrine disruption |
Concluded
|
Other
|
10-aug.-2018
|
Details | |
|
246-563-8
|
25013-16-5
|
France
|
Endocrine disruption |
Concluded
|
Restriction
|
30-jan.-2015
|
Details | |
|
202-830-0
|
100-21-0
|
France
|
Endocrine disruption |
Concluded
|
None
|
07-mar.-2017
|
Details | |
|
203-585-2
|
108-46-3
|
Finland
|
Endocrine disruption |
Concluded
|
CLH
|
17-maj-2018
|
Details | |
|
231-512-4
|
7601-90-3
|
Germany
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
201-280-9
|
80-46-6
|
Germany
|
Endocrine disruption |
Concluded
|
SVHC
|
07-mar.-2017
|
Details | |
|
205-031-5
|
131-57-7
|
Denmark
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
203-615-4
|
108-78-1
|
France
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
224-208-8
|
4247-02-3
|
Denmark
|
Endocrine disruption |
Concluded
|
SVHC
|
23-jun.-2022
|
Details | |
|
201-545-9
|
84-61-7
|
Sweden
|
Endocrine disruption |
Concluded
|
SVHC
|
07-sep.-2015
|
Details | |
|
202-679-0
|
98-54-4
|
Germany
|
Endocrine disruption |
Concluded
|
SVHC
|
07-mar.-2017
|
Details | |
|
216-036-7
|
1478-61-1
|
Sweden
|
Endocrine disruption |
Concluded
|
CLH
|
05-dec.-2018
|
Details | |
|
201-025-1
|
77-40-7
|
France
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
205-029-4
|
131-56-6
|
Denmark
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
690-137-8
|
5436-43-1
|
France
|
Endocrine disruption |
Concluded
|
Other
|
30-jan.-2019
|
Details | |
|
205-028-9
|
131-55-5
|
Denmark
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
203-049-8
|
102-71-6
|
France
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
239-139-9
|
15087-24-8
|
Germany
|
Endocrine disruption |
Concluded
|
SVHC
|
10-jul.-2015
|
Details | |
|
214-946-9
|
1222-05-5
|
France
|
Endocrine disruption |
Concluded
|
Other
|
22-jan.-2020
|
Details | |
|
253-242-6
|
36861-47-9
|
Germany
|
Endocrine disruption |
Concluded
|
SVHC
|
10-jul.-2015
|
Details | |
|
253-242-6
|
36861-47-9
|
Denmark
|
Endocrine disruption |
Concluded
|
SVHC
|
04-dec.-2020
|
Details | |
|
203-726-8
|
109-99-9
|
Germany
|
Consumer use |
Concluded
|
CLH Restriction |
20-sep.-2022
|
Details | |
|
215-157-2
|
1308-06-1
|
Netherlands
|
Carcinogenic |
Concluded
|
SVHC
|
09-jun.-2017
|
Details | |
|
204-126-9
|
116-14-3
|
Ireland
|
Carcinogenic |
Concluded
|
CLH
|
31-okt.-2018
|
Details | |
|
Substances manufactured in form of fibres with length ≥ 5 µm, a diameter < 3 µm and aspect ratio ≥ 3:1 as well as fibres released from substances, mixtures or articles during their life cycle due to mechanical effects (e.g. breaking/splicing), chemical processes (e.g. oxidation/ageing) or physical conditions (e.g. heat), excluding asbestos
|
-
|
-
|
Germany
|
Carcinogenic |
Concluded
|
Restriction
|
30-maj-2023
|
Details |
|
202-051-6
|
91-22-5
|
Sweden
|
Carcinogenic |
Concluded
|
Restriction
|
28-jan.-2022
|
Details | |
|
show/hide
A mixture of: propan-2-one-O,O'(methoxyvinylsilandiyl)dioxime; propan-2-one-O-(dimethoxyvinylsilyl)oxime; propan-2-one-O,O',O''-(vinylsilantriyl)trioxime
WASOX-VMAC2
EC / List no:
458-680-3
| CAS no:
797751-44-1
A mixture of: propan-2-one-O,O'-(methoxymethylsilandiyl)dioxime; propan-2-one-O-(dimethoxymethylsilyl)oxime; propan-2-one-O,O',O''-(methylsilantriyl)trioxime
WASOX-MMAC2
EC / List no:
460-110-3
| CAS no:
-
5-ethyl-2,8-dimethyl-5-[(propan-2-ylideneamino)oxy]-4,6-dioxa-3,7-diaza-5-silanona-2,7-diene
EC / List no:
611-631-1
| CAS no:
58190-57-1
|
-
|
-
|
Germany
|
Carcinogenic |
Concluded
|
CLH Restriction Other |
15-jul.-2021
|
Details |
|
207-069-8
|
431-03-8
|
Netherlands
|
Carcinogenic |
Concluded
|
CLH
|
16-feb.-2023
|
Details | |
|
233-660-5
|
10294-40-3
|
Netherlands
|
Carcinogenic |
Concluded
|
CLH
|
28-maj-2019
|
Details | |
|
202-681-1
|
98-56-6
|
Netherlands
|
Carcinogenic |
Concluded
|
CLH Restriction Other legislation Other |
17-mar.-2021
|
Details | |
|
FLORHYDRAL
|
412-050-4
|
125109-85-5
|
ECHA
|
Under development
|
CCH
|
02-maj-2022
|
Details | |
|
271-795-1
|
68608-68-4
|
ECHA
|
Under development
|
No action
|
02-maj-2022
|
Details | ||
|
284-219-9
|
84812-94-2
|
ECHA
|
Under development
|
CCH
|
02-maj-2022
|
Details | ||
|
290-475-2
|
90170-42-6
|
ECHA
|
Under development
|
CCH
|
02-maj-2022
|
Details | ||
|
290-476-8
|
90170-43-7
|
ECHA
|
Under development
|
Pending action
|
02-maj-2022
|
Details | ||
|
298-632-7
|
93820-52-1
|
ECHA
|
Under development
|
No action
|
23-jun.-2022
|
Details | ||